Disparities in renal replacement in lupus nephritis: Current practice and future implications

Arthritis Care and Research

Volumn 63, Issue 12, 2011, Pages 1639-1641

  Ishimori, Mariko L ^a   Gudsoorkar, Vineet ^a   Venuturupalli, Swamy R ^a   Weisman, Michael H ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; AGED; COMORBIDITY; CONTROLLED STUDY; DATA BASE; HEALTH DISPARITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL PRACTICE; MEDICARE; MORBIDITY; PERITONEAL DIALYSIS; PREVALENCE; RACE DIFFERENCE; RENAL REPLACEMENT THERAPY; REVIEW; UNITED STATES; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; ETHNOLOGY; FEMALE; HEALTH CARE DISPARITY; MALE; MINORITY GROUP; NOTE; PATIENT SELECTION; STATISTICS;

FEMALE; HEALTHCARE DISPARITIES; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MINORITY GROUPS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; RENAL REPLACEMENT THERAPY;

EID: 84856021211     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20611     Document Type: Review

References (20)

1. Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms: the high prevalence in black women. Arch Intern Med 1974;134: 1027-35.
2. Hochberg MC. The incidence of systemic lupus erythemato-sus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985;28:80-6. (Pubitemid 15193025)
3. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus ery-thematosus: race and gender differences. Arthritis Rheum 1995;38:1260-70.
4. Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G Jr, Vila LM, et al, for the LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007;57:576-84. (Pubitemid 46764046)
5. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161-7. (Pubitemid 34296931)
6. Devlin A, Waikar S, Solomon DH, Lu B, Shakevich T, Alarcon GS, et al. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) 2011;63:1642-53.
7. US Renal Data System. 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
8. Rietveld A, Berden JH. Renal replacement therapy in lupus nephritis. Nephrol Dial Transplant 2008;23:3056-60.
9. Ayanian JZ, Cleary PD, Keough JH, Noonan SJ, David-Kasdan JA, Epstein AM. Physicians' beliefs about racial differences in referral for renal transplantation. Am J Kidney Dis 2004;43: 350-7. (Pubitemid 38146334)
10. Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 1983;308:186-90. (Pubitemid 13171137)
11. Craddock PR. End stage renal disease in systemic lupus ery-thematosus letter. N Engl J Med 1983;308:1537.
12. Vanholder R, van Laecke S, Glorieux G. The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity? J Nephrol 2008;21:146-60.
13. Mehrotra R, Marsh D, Vonesh E, Peters V, Nissenson A. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney Int 2005;68:378-90. (Pubitemid 43181398)
14. Burkart J. The future of peritoneal dialysis in the united states: optimizing its use. Clin J Am Soc Nephrol 2009;4: S125-31.
15. Kutner NG, Zhang R, Huang Y, Wasse H. Patient awareness and initiation of peritoneal dialysis. Arch Intern Med 2011; 171:119-24.
16. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, Hispanic, and older patients with chronic renal failure. Am J Kidney Dis 1999;33:728-33. (Pubitemid 29159940)
17. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039-46. (Pubitemid 37220309)
18. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophos-phamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
19. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72. (Pubitemid 28313416)
20. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomeru-lonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-13. (Pubitemid 34303813)